Comparative Pharmacology
Head-to-head clinical analysis: GENTAK versus KANAMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAK versus KANAMYCIN SULFATE.
GENTAK vs KANAMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing mRNA misreading.
Gentamicin 3-5 mg/kg IV or IM once daily; alternatively, 1.5-2.5 mg/kg IV or IM every 8 hours.
15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.
None Documented
None Documented
2–3 hours in adults with normal renal function; prolonged to 24–60 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 30-60 hours in severe renal impairment (CrCl <10 mL/min).
Renal excretion of unchanged drug accounts for >90% of elimination; <5% biliary/fecal.
Renal excretion of unchanged drug accounts for 80-90% of elimination; minor biliary excretion (<1%) and fecal elimination (<1%).
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic